Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phthisis Diagnostics Launches New Product Line

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
G-Sphere® Molecular Standards provides flexible quality control for labs.

Phthisis Diagnostics has just rolled out its new molecular standards product line, the G-Sphere® Molecular Standards.

The new line quickly follows the introduction of the company’s second product in its Simply Molecular® line of enzyme-based extraction kits for rapid sample preparation prior to PCR applications in laboratories.

Phthisis Diagnostics, based in Charlottesville, VA, is a rapidly growing biotechnology company developing a range of innovative molecular diagnostics technologies.

The G-Sphere® Molecular Standards are synthetic genes that provide safe, stable, consistent, and abundant controls for virtually any organism and any molecular assay.

Molecular diagnostic laboratories face difficulties in obtaining consistent and reliable controls to monitor the performance of molecular assays and instruments.

This new Phthisis product line, the only one currently offering such standards for parasites, is an innovative solution to improve and simplify quality control procedures.

The Company has expanded its staff to allow special focus on the development of the new line. Elizabeth Nelson is a Research Technician designated as the Project Lead for the G-Sphere® Molecular Standards.

This custom product is supplied as 100 reaction vials that come with dilution buffer and instructions for use. In addition to custom orders, a growing list of G-Sphere® Molecular Standards have been developed for various parasites, including Cryptosporidium, Giardia, Entamoeba, Plasmodium, Microsporidia, and other analytes of particular interest to public health laboratories.

“This new product provides much needed quality control standards to molecular laboratories,” explains Crystal Icenhour, PhD, President and Chief Science Officer at Phthisis Diagnostics.

Icenhour continued, “We have developed a consensus approach to creating molecular standards, giving the users greater flexibility. We are excited to introduce this product line because it will enable molecular laboratories to better control diagnostic assays. In addition to being a stand-alone product, these molecular standards will be used as positive controls for our diagnostic product line.”

Phthisis Diagnostics will be presenting its new product line for the first time at the 2012 Association for Molecular Pathology (AMP) Annual Meeting in Long Beach, CA, in October.

Interested laboratories are encouraged to stop by Phthisis’ Booth # 332 at this meeting to learn more about G-Sphere® Molecular Standards.

Phthisis Diagnostics products are developed and manufactured in the USA to ISO 13485 standards in a QSR and cGMP compliant facility and are designated as general purpose reagents.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phthisis Diagnostics Announces Second Round of Funding
With their first product already in the international marketplace and a second just launched, Phthisis Diagnostics has announced a successful second round of angel funding.
Thursday, July 12, 2012
Phthisis Diagnostics Announces First International Distribution Agreement
Simple and cost-efficient molecular products make their way into Latin America.
Friday, May 25, 2012
Phthisis Diagnostics Welcomes New Sales Director and Controller
Appointment of Betty Polk and Robert Owen to Company’s management team.
Monday, May 14, 2012
Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!